1. Exact Sciences will announce Q2 2025 financial results on August 6, 2025. 2. Management will host a conference call to discuss results and progress. 3. The company's portfolio includes key products like Cologuard and Oncotype DX. 4. Exact Sciences continues investing in advanced cancer diagnostic solutions. 5. A replay of the webcast will be available for all interested parties.
While earnings calls can influence stock prices, the release date is far off. Historical precedent shows that announcements have limited immediate effect unless groundbreaking data is presented.
As an upcoming earnings event, it is critical for stakeholders and could influence future projections for EXAS.
The financial results and call could shape investor sentiment over the longer term, especially if new product data is revealed.
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2025 financial results after the close of the U.S. financial markets on August 6, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Second quarter 2025 webcast & conference call details
Date: |
Wednesday, August 6, 2025 |
|
Time: |
5 p.m. ET |
|
Webcast: |
The live webcast can be accessed at www.exactsciences.com |
|
Telephone: |
Domestic callers, dial 888-330-2384 Access code for both domestic and international callers: 4437608 |
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences helps patients and health care providers make timely, informed decisions before, during, and after a cancer diagnosis. The company’s growing portfolio includes well-established brands such as Cologuard® and Oncotype DX®, along with innovative solutions like Oncodetect™ for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com, follow @ExactSciences on X, or connect on LinkedIn and Facebook.